drugset / Trial / NCT00267215

Efficacy and Safety of Lumiracoxib

NCT00267215

Phase 3 Completed 330 enrolled Novartis
RandomizedParallel-groupDouble-blindTreatment

Summary

This trial assessed the safety and efficacy of a single dose of lumiracoxib 400 mg compared to placebo and to a single dose of celecoxib 200mg. It also assessed safety and efficacy of 400mg lumiracoxib administered once a day for 7 days compared to placebo and to 200 mg celecoxib twice daily.

Timeline

Start
2000-11
Primary completion
2001-02
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Lumiracoxib Small molecule 400 mg

Indications